Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder

Conclusions Disability outcomes were more favorable with inebilizumab vs placebo in participants with NMOSD. Classification of Evidence This study provides Class II evidence that for patients with NMOSD, inebilizumab reduces the risk of worsening disability. N-MOmentum is registered at ClinicalTrials.gov: NCT02200770.

http://nn.neurology.org/cgi/content/short/8/3/e978?rss=1

Source: Neurology Neuroimmunology and Neuroinflammation - March 26, 2021 Category: Neurology Authors: Marignier, R., Bennett, J. L., Kim, H. J., Weinshenker, B. G., Pittock, S. J., Wingerchuk, D., Fujihara, K., Paul, F., Cutter, G. R., Green, A. J., Aktas, O., Hartung, H.-P., Lublin, F. D., Williams, I. M., Drappa, J., She, D., Cimbora, D., Rees, W., Smit Tags: Autoimmune diseases, All Clinical Neurology, Clinical trials Randomized controlled (CONSORT agreement), Class II, Devic's syndrome Article Source Type: research